Clinical Trial Update: A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI [Phase 2]

View source ↗

Summary

A completed Phase 2 trial investigating the prevalence of pancreatic exocrine insufficiency in Type 2 diabetes patients and how a single dose of EPANOVA or OMAC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency
• Type 2 Diabetes Mellitus

Drugs mentioned

• Epanova (icosapent ethyl)
• Omacor (omega-3-acid ethyl esters)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency | Phase 2 | Status: COMPLETED | Results posted: 2017-01-20